Abstract
Elevated nighttime blood pressure (BP) and a reduced day-night BP fall ("nondipping" condition) are strong predictors of cardiovascular complications, both in hypertension and in the general population. A reduced or inverted nocturnal BP fall might also be theoretically used to define the most appropriate timing for drug administration. In a systematic review of the available evidence, we show that bedtime dosing of antihypertensive medication reduces nocturnal BP and increases day-night BP fall more than standard morning dosing. The effects of such an approach on average 24-hour BP are more modest and less univocal, with a considerable betweencenter heterogeneity. Admittedly, the mechanisms underlying non-dipping condition have not been fully understood yet, and it is still a matter of debate whether restorating a dipping pattern may reduce the cardiovascular risk associated with non-dipping independently from the effects on 24-hour BP. Under this regard, evidence from a single trial strongly suggests that bedtime dosing of antihypertensive medications may greatly reduce cardiovascular morbidity in hypertensive patients. The provocative results of that trial deserve to be explored further in larger intervention trials.
Keywords: Hypertension, treatment, chronotherapy, nocturnal blood pressure, dipping.
Current Pharmaceutical Design
Title:Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Volume: 21 Issue: 6
Author(s): Giuseppe Schillaci, Francesca Battista, Laura Settimi and Luca Schillaci
Affiliation:
Keywords: Hypertension, treatment, chronotherapy, nocturnal blood pressure, dipping.
Abstract: Elevated nighttime blood pressure (BP) and a reduced day-night BP fall ("nondipping" condition) are strong predictors of cardiovascular complications, both in hypertension and in the general population. A reduced or inverted nocturnal BP fall might also be theoretically used to define the most appropriate timing for drug administration. In a systematic review of the available evidence, we show that bedtime dosing of antihypertensive medication reduces nocturnal BP and increases day-night BP fall more than standard morning dosing. The effects of such an approach on average 24-hour BP are more modest and less univocal, with a considerable betweencenter heterogeneity. Admittedly, the mechanisms underlying non-dipping condition have not been fully understood yet, and it is still a matter of debate whether restorating a dipping pattern may reduce the cardiovascular risk associated with non-dipping independently from the effects on 24-hour BP. Under this regard, evidence from a single trial strongly suggests that bedtime dosing of antihypertensive medications may greatly reduce cardiovascular morbidity in hypertensive patients. The provocative results of that trial deserve to be explored further in larger intervention trials.
Export Options
About this article
Cite this article as:
Schillaci Giuseppe, Battista Francesca, Settimi Laura and Schillaci Luca, Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension, Current Pharmaceutical Design 2015; 21 (6) . https://dx.doi.org/10.2174/1381612820666141024130013
DOI https://dx.doi.org/10.2174/1381612820666141024130013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Hyperuricemia and Coronary Artery Disease
Current Rheumatology Reviews Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Adipoparacrinology of Atherosclerosis: Evidence Updated
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging α2-Antiplasmin on Cardiovascular Diseases
Current Pharmaceutical Design Candidate Genes in the Pharmacogenomics of Antihypertensive Treatment - A Review and Future Aspects
Current Pharmacogenomics Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review
Current Vascular Pharmacology Goal Directed Fluid Therapy
Current Pharmaceutical Design Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews A Lack of Association Between Blood Glutamate and Anxiety Levels in Pre- delivery Pregnant Women
Current Pharmaceutical Analysis Nutrition and Physical Activity on Hypertension: Implication of Current Evidence and Guidelines
Current Hypertension Reviews Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Inhibition of Candida rugosa Lipase by Secondary Metabolites Extracts of Three Algerian Plants and their Antioxydant Activities
Current Enzyme Inhibition Meet Our Editor
Current Clinical Pharmacology Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology